Title: Cytokeratin 18 can help predict liver fibrosis in HCV infected patients with type 2 diabetes
mellitus
Version: 1 Date: 01 Sep 2021
Reviewer's report:
The study assessed the value of cytokeratin 18 in the assessment of liver fibrosis in hcv diabetic
patients, however, there are two major concerns:
- Sample size calculation is important for the results to be valid.
- Absence of control group of hcv patients and non diabetic is a major limitation.
Moreover, being a retrospective study may increase the risk of bias.
Title: Cytokeratin 18 can help predict liver fibrosis in HCV infected patients with type 2 diabetes
mellitus
Version: 1 Date: 01 Sep 2021
Reviewer's report:
The study assessed the value of cytokeratin 18 in the assessment of liver fibrosis in hcv diabetic
patients, however, there are two major concerns:
- Sample size calculation is important for the results to be valid.
- Absence of control group of hcv patients and non diabetic is a major limitation.
Moreover, being a retrospective study may increase the risk of bias.
Please review this paper.
user
Title: Cytokeratin 18 can help predict liver fibrosis in HCV infected patients with type 2 diabetes
mellitus
Version: 1 Date: 01 Sep 2021
Reviewer's report:
The study assessed the value of cytokeratin 18 in the assessment of liver fibrosis in hcv diabetic
patients, however, there are two major concerns:
- Sample size calculation is important for the results to be valid.
- Absence of control group of hcv patients and non diabetic is a major limitation.
Moreover, being a retrospective study may increase the risk of bias.
assistant